Not yet recruiting
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Not yet recruiting
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
NCT07818356· Phase 4· University Hospital, Toulouse· Source
Not yet recruiting
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
NCT07836283· Phase 3· University Hospital, Rouen· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source
Not yet recruiting
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
2025-524976-40-00· Phase 3· Centre Hospital Region Metz Thionville· Source
Not yet recruiting
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
NCT07152184· Phase 2· University Hospital, Strasbourg, France· Source
Not yet recruiting
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Not yet recruiting
Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients
NCT07679841· Phase 1/2· Centre Leon Berard· Source
Recruiting
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
NCT07189325· Phase 3· University Hospital, Montpellier· Source
Recruiting
Efficacy of Early Continuous Infusion of HSS on the Neurological Outcome at 6 Months in TBI Patients.
NCT07319208· Phase 3· Nantes University Hospital· Source
Recruiting
Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI
NCT07164859· Phase 3· Vincent ROULE· Source
Not yet recruiting
Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
NCT07451847· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
NCT06940661· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
2024-518385-26-01· Phase 3· Centre Hospitalier Regional Et Universitaire De Brest· Source
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Hoffmann-La Roche· Source
Recruiting
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835· Phase 2· Zydus Therapeutics Inc.· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700· Phase 3· Merz Therapeutics GmbH· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713· Phase 3· Merz Therapeutics GmbH· Source
Recruiting
Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
NCT06906549· Phase 4· University Hospital, Strasbourg, France· Source
Recruiting
JAK Inhibitor Dose TAPering Strategy Study
NCT06687551· Phase 4· University Hospital, Toulouse· Source
Recruiting
Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke
NCT06768138· Phase 3· Central Hospital, Nancy, France· Source
Recruiting
Capsaicin in Digital Osteoarthritis Versus Control
NCT06444919· Phase 4· University Hospital, Clermont-Ferrand· Source
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· Phase 3· AstraZeneca· Source
Recruiting
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma
2024-516709-22-00· Phase 2/3· Centre Hospitalier Regional Universitaire· Source
Recruiting
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955· Phase 3· Hoffmann-La Roche· Source
Recruiting
Short versus long antiplatelet therapy after TAVI
2023-508208-40-00· Phase 2/3· Centre Hospitalier Universitaire De Caen Normandie· Source
Active, not recruiting
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060· Phase 2· Ipsen· Source
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· Phase 3· UNICANCER· Source
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955· Phase 3· Ferring Pharmaceuticals· Source
Recruiting
“Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis” - FOCUS
2023-505112-38-00· Phase 4· Assistance Publique Hopitaux De Paris· Source
Recruiting
UVB: treatment of UVeitis in Behçet’s diseases with biologic
2024-513371-41-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Recruiting
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH
NCT05860699· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
TocilizuMab discontinuAtion in GIant Cell Arteritis
2023-505515-21-00· Phase 3· Centre Hospitalier Universitaire De Dijon· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Recruiting
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
NCT06269900· Phase 3· Nantes University Hospital· Source
Recruiting
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT05674994· Phase 3· Fondation Hôpital Saint-Joseph· Source
Recruiting
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
NCT05260528· Phase 2· Centre Hospitalier Universitaire de Nice· Source
Active, not recruiting
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399· Phase 3· Bristol-Myers Squibb· Source
Recruiting
ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care
2024-513327-16-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Baricitinib in Patients With Relapsing or naïve Dermatomyositis
NCT04972760· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Recruiting
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
NCT04702256· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
Pulmonary Embolism International THrOmbolysis Study-3
NCT04430569· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Showing 50 of 63.